MSB (ASX) The case for Meso's CLBP

Originally posted by The Yankee ↑

From a sheer numbers perspective, there are 23 million people in the US alone that suffer from CLBP.
CLBP is a unique condition in that it affects working age folks too and the lost productivity/workdays affecting bottom line for companies across all sectors is humongous. So it's not just a health issue but an "industrial" issue.
Some here suggested perhaps a better partner for Mesoblast would not be big pharma but an "outsider". I agree, at least in the CLBP space.

Yesterday, I posted about Eli Lilly's and Pfizer's Tanezumab and how they are targeting CLBP and Osteoarthritis using anti Nerve Growth Factors (NGF). Here some more perspective:
1. The FDA is desperate for non-opioid painkillers

2. The desperation shows clearly. Despite two prior clinical trial holds due to aggravation of the very problem Tanezumab was intended to solve, and despite adverse side effects, the FDA - and this is kinda comical and strange - lifted the clinical trial holds after a review of a robust body of nonclinical data. Yes, NON-CLINICAL data. Hmm.

Perhaps it is not really comical and strange keeping in mind the FDA's desperation.

3. HotCopper does not allow linking to this article, but you can Google "Tanezumab EP Vantage" and it is the first hit that comes up. It is an unbiased article about this space.
The author is not short or long any stocks mentioned and does even write about the share prices. Just lays out the science and compares various clinical trials and their progress.
The author is JUST NOT AWARE of Mesoblast's CLBP treatment. Surprise anyone?

4. Lilly and Pfizer may eventually get Tanezumab approved (they got the Fast Track from the FDA despite all the hiccups, so with their clout, I am pretty sure they will get this "approved"). But here is the thing:
Given the history of the anti-nerve growth factor agent means its safety will be under scrutiny.

5. Finally, here lies Mesoblast's grand opportunity since there is no competition. The opioid crisis is getting a lot of press and lots of dollars in federal grants. Mesoblast has to keep pounding on the FDA's doors to get the RMAT designation for CLBP. Full court press.
I am not sure what they are doing though. No one knows and I haven't seen any updates from the company on the status of their applications for RMAT. The CLBP opportunity is bigger than any other treatments that this company has in the pipeline.

It's thin at the top, Silviu. Get off your whatever and seize the freaking opportunity, coz no matter what, time is not an unlimited resource.
I am invested in this company not because of its management.

Expand

Thanks for posting. Appreciate it a lot. The author of the article you refer to may not be aware of MSB's product but I've seen it discussed online; they've looked up phase 3 trials and like the idea of a treatment that 'works with the body.'

I think the problem with the MaBs drugs is the publicity surrounding Actemra deaths. These things seem to be getting more dangerous. 'Wonder drug' Canakinumab for CHF is also one I believe. FDA stopped clinical trial fof gouty arthritis as it was too dangerous for anything non life-threatening. Public Citizen said just a single dose raised the risk of serious infections.

No.	Vol.	Price($)
6	206912	$1.02

No.

Vol.

Price($)

206912

$1.02

Price($)	Vol.	No.
$1.03	37637	1

Price($)

Vol.

No.

$1.03

37637

No.	Vol.	Price($)
6	206912	1.015
8	195410	1.010
5	95607	1.005
7	208096	1.000
3	103747	0.995

No.

Vol.

Price($)

206912

1.015

195410

1.010

95607

1.005

208096

1.000

103747

0.995

Price($)	Vol.	No.
1.025	37637	1
1.030	29757	2
1.035	91225	3
1.040	72457	5
1.045	126212	4

Price($)

Vol.

No.

1.025

37637

1.030

29757

1.035

91225

1.040

72457

1.045

126212

(20min delay)
Last $1.02		Change 0.015(1.49%)		Mkt cap ! $1.164B

Open	High	Low	Value	Volume
$1.00	$1.04	94.0¢	$11.76M	11.90M

The case for Meso's CLBP, page-4

Koba, formerly a cobalt player, gears up to become newest explorer in the uranium state: South Australia

New results confirm Buena Vista's iron grades potential

Mineral Commodities to shut down Tormin mineral sands project as oil spill contaminates beach

Trimmed CPI figure provokes market jump of 1%, but inflation pressures remain a reality

One Click Group jumps 4% after ending quarter with $2.4M in cash; $1M in revenue and 150K+ users on board

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The case for Meso's CLBP, page-4

Top Stories

Koba, formerly a cobalt player, gears up to become newest explorer in the uranium state: South Australia

New results confirm Buena Vista's iron grades potential

Mineral Commodities to shut down Tormin mineral sands project as oil spill contaminates beach

Trimmed CPI figure provokes market jump of 1%, but inflation pressures remain a reality

One Click Group jumps 4% after ending quarter with $2.4M in cash; $1M in revenue and 150K+ users on board

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News